CARTEOLOL HYDROCHLORIDE

Post-LOE

carteolol hydrochloride

Novartis

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Jan 2000

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

CARTEOLOL HYDROCHLORIDE (carteolol hydrochloride) by Novartis is clinical pharmacology carteolol is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. First approved in 2000.

Drug data last refreshed 17h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Carteolol is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Carteolol Hydrochloride reduces normal and elevated intraocular pressure (IOP) whether or not accompanied by…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on CARTEOLOL HYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.